{"id":641630,"date":"2026-08-17T11:00:17","date_gmt":"2026-08-17T11:00:17","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/641630\/"},"modified":"2026-08-17T11:00:17","modified_gmt":"2026-08-17T11:00:17","slug":"eli-lillys-lly-growth-story-keeps-adding-chapters","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/641630\/","title":{"rendered":"Eli Lilly\u2019s (LLY) Growth Story Keeps Adding Chapters"},"content":{"rendered":"\n

On August 5, Eli Lilly (NYSE:LLY<\/strong><\/a>) told investors its second quarter delivered 48% revenue growth, and the days since have brought even more good news. A UK regulatory approval, a new Medicare access program, and a pipeline addition have all landed in the same short stretch. For a stock that already dominates weight loss, the story now reads less like one hit product and more like an ecosystem built to catch every kind of patient. <\/p>\n

\"Eli<\/a> Eli Lilly’s (LLY) Growth Story Keeps Adding Chapters Bull Case: A Pill For Every Patient <\/p>\n

The clearest proof point arrived later on August 10, when the UK’s Medicines and Healthcare products Regulatory Agency approved Foundayo, Lilly’s oral GLP-1, for weight management and type 2 diabetes. It made Britain the first European market to greenlight the pill, and the stock rose nearly 4% on the news. Foundayo arrived second to Novo Nordisk’s oral Wegovy there, but it carries one edge: patients don’t need to fast for 30 minutes before taking it, unlike Wegovy’s tablet. Lilly said Foundayo is now under regulatory review in more than 40 additional countries, with a global rollout expected across major markets in 2027. <\/p>\n

Lilly is also stacking distinct treatments instead of leaning on one blockbuster. Zepbound remains the injectable leader, Foundayo serves needle-averse patients, and retatrutide, which just posted positive results across three Phase 3 trials, is being positioned for people who need deeper weight loss or have complications like sleep apnea. More than 80% of Foundayo prescriptions have gone to patients who had never taken a GLP-1 before, meaning Lilly is expanding its market rather than cannibalizing Zepbound. That breadth showed in the numbers: second-quarter revenue climbed 48% year-over-year, adjusted EPS hit $8.38, and management raised full-year revenue guidance to $85 billion to $87 billion. <\/p>\n

Bear Case: Paying Up For Perfection <\/p>\n

None of this comes cheap. Lilly trades at 32.47 times forward earnings as of August 14, well above the 18.5 times average for healthcare stocks, a multiple that assumes growth keeps compounding without a stumble. Mounjaro and Zepbound alone made up 65% of second-quarter revenue, so a slowdown in either would hit harder than it would a more diversified peer. There’s also a pricing trade-off inside the growth: average realized prices across Lilly’s GLP-1 portfolio fell 13% year over year, largely because the company keeps cutting prices to widen access, including a Zepbound price cut last December. Volume more than offset it, up 60% over the same stretch, but that formula depends on demand staying just as price-sensitive going forward. <\/p>\n

Competition is building too. Novo Nordisk had Wegovy’s pill on the UK market two months before Foundayo arrived, and its next-generation CagriSema is coming, even though a head-to-head trial showed Zepbound beating it. Semaglutide’s patent protection also expires this year in India, China, and Brazil, opening the door to generic rivals in fast-growing markets. <\/p>\n

What The Smart Money Sees <\/p>\n

Hedge fund ownership of Eli Lilly slipped from 137 funds to 132 in the most recent quarter, a modest pullback rather than a rush for the exits. Short interest sits at just 1.02% of the float, suggesting almost no organized bet against the stock. The stock’s forward price-to-earnings ratio confirms investors are still paying a growth premium even as fund positioning cools. <\/p>\n

The Next Chapter Turns <\/p>\n

Eli Lilly has turned a single weight-loss drug into a multi-product platform spanning injectables and pills, while regulators keep clearing new markets for Foundayo. The raised guidance and the Medicare access expansion both point toward more patients affording these drugs going forward. But the valuation leaves little cushion, and a portfolio still concentrated in two drugs means the bear case hinges on whether rivals like CagriSema or generic semaglutide start pulling volume away. <\/p>\n

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the <\/a>best short-term AI stock<\/strong><\/a>. <\/p>\n

READ NEXT: <\/strong>10 Best Future Stocks to Buy Under $10<\/strong><\/a> and <\/strong>12 Best Performing Semiconductor Stocks to Invest In<\/strong><\/a>.<\/strong> <\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/strong><\/a>.<\/strong> <\/p>\n","protected":false},"excerpt":{"rendered":"On August 5, Eli Lilly (NYSE:LLY) told investors its second quarter delivered 48% revenue growth, and the days…\n","protected":false},"author":2,"featured_media":641631,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[275],"tags":[18,1465,135,475,474,19,17,145,6526,14609,564],"class_list":["post-641630","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-eire","tag-eli-lilly","tag-health","tag-health-care","tag-healthcare","tag-ie","tag-ireland","tag-medicare","tag-novo-nordisk","tag-revenue-growth","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/117110507263724803","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/641630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=641630"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/641630\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/641631"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=641630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=641630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=641630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}